This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Andersen, R. V. Articles by Nordestgaard, B.o. G. Search for Related Content PubMed PubMed Citation Articles by Andersen, R. V. Articles by Nordestgaard, B.o. G.

Hepatic lipase mutations,elevated high-density lipoprotein cholesterol, and increased risk of ischemic heart disease

The Copenhagen City Heart Study

Rolf V. Andersen, MSc, PhD^*, Hans H. Wittrup, MD, PhD^*, Anne Tybjærg-Hansen, MD, DMSc, Rolf Steffensen, MD, Peter Schnohr, MD and B.ørge G. Nordestgaard, MD, DMSc^*,*

^* Department of Clinical Biochemistry, Herlev University Hospital, Herlev, Denmark
Department of Clinical Biochemistry, Copenhagen University Hospital, Copenhagen, Denmark
Department of Medicine B, Division of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
Copenhagen City Heart Study, Bispebjerg University Hospital, University of Copenhagen, Copenhagen, Denmark

View larger version (45K): [in a new window]   Figure 1 Levels of lipids and lipoproteins in individuals from the general population who are wild-type (Wild), triple heterozygotes (Hetero), or triple mutation homozygotes (Homo) for hepatic lipase promoter single nucleotide polymorphisms. A, C = women; B, D = men. ANOVA = analysis of variance; post-hoc Mann-Whitney U test: *p < 0.05; **p < 0.01; ***p < 0.001. HDL = high-density lipoprotein. E, G = women; F, H = men.

View larger version (37K): [in a new window]   Figure 2 Levels of high-density lipoprotein (HDL) cholesterol and apolipoprotein AI in individuals from the general population who are wild-type (Wild), triple heterozygotes (Hetero), or triple mutation homozygotes (Homo) for hepatic lipase promoter single nucleotide polymorphisms, stratified for apolipoprotein E genotype. The p values are by analysis of variance within each apolipoprotein E genotype stratum; post-hoc Mann-Whitney U test. *p < 0.05; **p < 0.01; ***p < 0.001. A, B = women. C, D = men.

View larger version (18K): [in a new window]   Figure 3 Risk of ischemic heart disease in prospective study analyzed by Cox regression. Results are relative risks (95% confidence interval [CI]): CI is not corrected for multiple comparisons. Individuals on cholesterol-lowering treatment (53 subjects, 8 events) and with unknown treatment status (87 subjects, 8 events) were excluded. *No homozygotes among cases in the 32 strata. HDL = high-density lipoprotein; IHD = ischemic heart disease.

View larger version (17K): [in a new window]   Figure 4 Risk of ischemic heart disease in case-control study analyzed by unconditional logistic regression. Results are odds ratios (95% confidence interval [CI]): CI is not corrected for multiple comparisons. Individuals on cholesterol-lowering treatment (122 cases, 45 controls) and with unknown treatment status (15 cases, 79 controls) were excluded. HDL = high-density lipoprotein.